Durvalumab combined with BCG cuts recurrence risk by 32% in phase 3 trial for high-risk non-muscle-invasive bladder cancer
A phase 3 study called POTOMAC tested durvalumab together with BCG induction and maintenance against BCG alone in patients who had not previously received BCG and who have high-risk non-muscle-invasive bladder cancer.
The combination therapy achieved a hazard ratio of 0.68 for disease‑free survival, meaning a 32% lower risk of recurrence or death compared with BCG alone.
These results suggest that adding durvalumab to standard BCG treatment could improve outcomes for a difficult-to‑treat bladder cancer population, pending further regulatory review and potential approval.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial”
read at onclive ↗
comments(0)
5-min edit window · permanent after that